| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.7M | — | +221.8% |
| SG&A Expense | $34.2M | — | +1064.8% |
| Operating Income | -$50.1M | — | -442.9% |
| Interest Expense | $0 | — | -100.0% |
| Income Tax | $0 | — | — |
| Net Income | -$48.3M | — | -310.6% |
| EPS (Basic) | -$0.54 | — | -14.9% |
| EPS (Diluted) | -$0.54 | — | -14.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $189.0M | +4.0% | +376.2% |
| Accounts Receivable | $632K | +3.8% | — |
| Inventory | $1.5M | +3.3% | +12.4% |
| Current Assets | $194.2M | +3.6% | +341.3% |
| Total Assets | $269.9M | +2.6% | +108.7% |
| Current Liabilities | $4.2M | -45.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$31.3M | — | -223.0% |
| Capital Expenditures | $576K | — | +236.8% |
| Investing Cash Flow | -$508K | — | -345.6% |
| Financing Cash Flow | $39.3M | — | — |
| Free Cash Flow | -$31.9M | — | -223.2% |
| +54.5% |
| Total Liabilities | $46.1M | -6.5% | -73.5% |
| Stockholders' Equity | $223.8M | +4.7% | +602.9% |